A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer-Reference-Cited by-同舟云学术

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer

Published:2015-03-12 Issue:7 Volume:112 Page:1215-1222
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Koti M,Siu A,Clément I,Bidarimath M,Turashvili G,Edwards A,Rahimi K,Masson A-M M,Squire J A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201581.pdf

Reference43 articles.

1. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, Marincola FM, Manjili MH (2012) A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 131: 871–880.

2. Baxevanis CN, Papamichail M, Perez SA (2013) Immune classification of colorectal cancer patients: impressive but how complete? Expert Opin Biol Ther 13: 517–526.

3. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, Squire JA, Macgregor PF (2005) High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7: 603–613.

4. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pages F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39: 782–795.

5. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA (2014) Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24: 743–750.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential tools for predicting response to chemotherapy in OC: Assessment of immune dysbiosis, participant’s self-rated health and microbial dynamics;Journal of Reproductive Immunology;2024-06

2. Drug resistance in ovarian cancer: from mechanism to clinical trial;Molecular Cancer;2024-03-28

3. Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer;Cancers;2023-04-18

4. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer;Journal for ImmunoTherapy of Cancer;2023-04

5. Niraparib in the treatment of ovarian cancer: A comprehensive review;National Journal of Pharmacology and Therapeutics;2023